<DOC>
	<DOCNO>NCT01722526</DOCNO>
	<brief_summary>To evaluate safety , tolerability , pharmacokinetic , pharmacodynamic profile rhASM adult patient Acid Sphingomyelinase Deficiency ( ASMD ) follow repeated-dose administration .</brief_summary>
	<brief_title>Tolerability Safety Study Recombinant Human Acid Sphingomyelinase Acid Sphingomyelinase Deficiency Patients</brief_title>
	<detailed_description />
	<mesh_term>Niemann-Pick Disease , Type A</mesh_term>
	<mesh_term>Niemann-Pick Diseases</mesh_term>
	<mesh_term>Niemann-Pick Disease , Type C</mesh_term>
	<criteria>Patients document nonneuronopathic acid sphingomyelinase deficiency The patient diffuse capacity carbon monoxide ( DLco ) &gt; 20 % ≤80 % predict normal value . The patient spleen volume ≥6 multiples normal ( MN ) . A partial splenectomy permit perform ≥1 year prior Screening/Baseline residual spleen volume ≥6 MN . The patient receive lipid lower therapy stable dose regimen lipidlowering therapy ( y ) least 12 week prior Screening/Baseline , patient expect remain dose regimen throughout 26week treatment period . The patient female childbearing potential must negative serum pregnancy test βHCG . The patient female pregnant lactating . The patient Body Mass Index ( BMI ) &gt; 30 . The patient receive investigational drug within 30 day prior study enrollment The patient medical condition extenuate circumstance may significantly interfere study compliance , include prescribed evaluation followup activity . The patient major organ transplant ALT AST &gt; 250 IU/L total bilirubin &gt; 1.5 mg/dL . The patient unwilling unable abstain use alcohol 1 day prior 3 day rhASM infusion duration study . The patient require medication may decrease rhASM The patient unwilling unable avoid use medication herbal supplement may cause prolong bleeding , potential hepatotoxicity within 10 day prior 3 day liver biopsy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Human acid sphingomyelinase deficiency</keyword>
</DOC>